Both GTx Inc. (NASDAQ:GTXI) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ) are each other’s competitor in the Biotechnology industry. Thus the contrast of their institutional ownership, analyst recommendations, profitability, risk, dividends, earnings and valuation.

Earnings & Valuation

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
GTx Inc.	N/A	0.00	38.42M	-1.87	0.00
Jazz Pharmaceuticals plc	1.89B	4.14	447.10M	5.93	22.69

Table 1 shows the top-line revenue, earnings per share and valuation for GTx Inc. and Jazz Pharmaceuticals plc.

Profitability

Table 2 represents GTx Inc. (NASDAQ:GTXI) and Jazz Pharmaceuticals plc (NASDAQ:JAZZ)’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
GTx Inc.	0.00%	-126.4%	-100.3%
Jazz Pharmaceuticals plc	23.66%	15.2%	8.2%

Risk & Volatility

GTx Inc. has a beta of 2.56 and its 156.00% more volatile than Standard & Poor’s 500. Jazz Pharmaceuticals plc’s 23.00% more volatile than Standard & Poor’s 500 volatility due to the company’s 1.23 beta.

Liquidity

The current Quick Ratio of GTx Inc. is 4.3 while its Current Ratio is 4.3. Meanwhile, Jazz Pharmaceuticals plc has a Current Ratio of 4.3 while its Quick Ratio is 4.2. is better positioned to pay off its short-term and long-term debts than .

Analyst Recommendations

GTx Inc. and Jazz Pharmaceuticals plc Ratings and Recommendations are available in the next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
GTx Inc.	0	0	0	0.00
Jazz Pharmaceuticals plc	0	3	8	2.73

Meanwhile, Jazz Pharmaceuticals plc’s consensus target price is $172, while its potential upside is 25.44%.

Institutional and Insider Ownership

The shares of both GTx Inc. and Jazz Pharmaceuticals plc are owned by institutional investors at 22.5% and 90.8% respectively. Insiders owned roughly 17.8% of GTx Inc.’s shares. Insiders Competitively, owned 2.5% of Jazz Pharmaceuticals plc shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
GTx Inc.	-3.85%	-8.26%	-29.58%	-95.1%	-93.57%	28.21%
Jazz Pharmaceuticals plc	6.52%	6.82%	-8.16%	-21.57%	-4.4%	8.49%

For the past year GTx Inc. was more bullish than Jazz Pharmaceuticals plc.

Summary

On 9 of the 10 factors Jazz Pharmaceuticals plc beats GTx Inc.

GTx, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of small molecules for the treatment of breast and prostate cancer, and other medical conditions. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, stress urinary incontinence (SUI), and Duchenne muscular dystrophy (DMD); and selective androgen receptor degraders (SARDs) to treat progressive castration-resistant prostate cancer (CRPC). The companyÂ’s lead SARM candidate is the enobosarm GTx-024, a Phase II open-label proof-of-concept clinical trial for patients with advanced androgen receptor (AR) positive triple-negative breast cancer; and estrogen receptor positive and AR positive advanced breast cancer, as well as postmenopausal women with SUI. GTx, Inc. was founded in 1997 and is headquartered in Memphis, Tennessee.

Jazz Pharmaceuticals Public Limited Company, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology. It markets Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in patients with narcolepsy; Erwinaze to treat acute lymphoblastic leukemia (ALL); Defitelio for the treatment and prevention of severe hepatic veno-occlusive disease, a potentially life-threatening complication of hematopoietic stem cell transplantation; and Prialt, an intrathecally administered infusion of ziconotide for the management of severe chronic pain. The company also develops JZP-110, which is in phase III clinical trial for the treatment of excessive sleepiness (ES) in patients with narcolepsy and obstructive sleep apnea, as well as phase II clinical trial for ES associated with ParkinsonÂ’s disease; Vyxeos (CPX-351) for high-risk acute myeloid leukemia; and JZP-507 and JZP-258 to treat EDS and cataplexy in narcolepsy, as well as evaluates deuterated oxybate for narcolepsy. In addition, it sells psychiatry and other products. The company is headquartered in Dublin, Ireland.